Phase 2 N=9 Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins
Multiple System Atrophy
Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm
Healthy
Primary: Change Sodium Blood Levels — 141.8; 141.2 mmol/L
Phase 2 N=32 Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia
Invasive Pulmonary Aspergillosis · Lymphoblastic Leukaemia · Myeloblastic Leukaemia
Primary: Number of Participants With Adverse Events That Results in the Interruption of Treatment, as a Measure of Safety and Tolerability — 0 participants
Phase 2 N=395 Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
Hepatitis C Virus
Primary: Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Extended Rapid Virologic Response (eRVR) — 54.4; 54.1; 13.9 percentage of participants
Phase 2 N=48 Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
Hepatitis C Infection
Primary: Percentage of Participants With Extended Rapid Virologic Response (eRVR) at Weeks 4 and 12 — 41.7; 83.3; 75; 8.3 percentage of participants
Phase 2 N=211 Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response at Post Treatment Week 12 (SVR12) — 96.4; 85.7; 95.0; 100.0 Percentage of participants
Phase 2 N=117 Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
Squamous Cell Non-small Cell Lung Cancer
Primary: Objective Response Rate (ORR) as Assessed by Independent Radiology Review Committee (IRC) — 14.5 Percentage of Participants
Phase 2 N=341 A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension
Essential Hypertension
Primary: Number of Participants With Adverse Events, Serious Adverse Events, and Deaths (Analysis by Actual Treatment) — 147; 78; 53; 0 Participants
Phase 2 N=39 Pharmacokinetic Study of Testosterone Enanthate
Hypogonadism
Primary: The Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Testosterone Enanthate Formulations at 6 Weeks — 150445.2; 70955.7; 278657.9…
Phase 2 N=172 Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy
Non-small Cell Lung Cancer
Primary: Overall Survival (OS) Time — 32.4; 32.2 Months — p=0.828
Phase 2 N=226 A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
Diabetic Nephropathy
Primary: Percent Reduction From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 — 13.27; 5.02 percent (%)
Phase 2 N=40 A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
Acute Ischemic Stroke
Primary: Incidence of Symptomatic Intracranial Hemorrhage (SICH) by Dose Cohort — 0; 0; 0 participants
Phase 2 N=303 UARK 2003-33, Total Therapy III
Multiple Myeloma
Primary: Percentage of Participants With Progression-Free Survival (PFS) at 3 Years From Initiation of Study Treatment — 77 percentage of participants
Phase 2 N=54 S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
Advanced Malignant Mesothelioma · Epithelial Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Overall Response Rate — 9 percentage of participants
Phase 2 N=47 Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer · Non-Small Cell Lung Cancer
Primary: Phase I: Maximum Tolerable Dose (MTD) of Dasatinib Given With Erlotinib Hydrochloride — 70 mg/day